🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT07829406
Starting soon Phase 1

A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People

NCT07829406 · tracked via the Priya Life Science USA tracker
Sponsor
Novo Nordisk A/S
Phase
Phase 1
Started
2026-09-17
Last updated
2026-09-21

Condition(s) studied

Healthy Volunteers

Investigational drug(s) / intervention(s)

NNC0642-1895Placebo

NNC0642-1895: NNC0642-1895 will be administered intravenously.

Placebo: Placebo will be administered intravenously.

Study summary

This study is testing a new medicine, in healthy adults to assess its safety and understand how it behaves in the body. The purpose of this study is to evaluate the safety, tolerability, and how the body responds to a single dose of NNC0642-1895 in healthy adults. Participant will either get study medicine (NNC0642-1895) or placebo (a treatment that has no active medicine in it). Which treatment a participant receives is decided by chance. NNC0642-1895 is a new medicine that is being tested in humans for the first time and is not currently available for doctors to prescribe. The study will last for about 94 days (approximately 14 weeks).

Eligibility

Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18-55 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) between 18.5 to 29.9 kilogram per square meter (kg/m\^2) (both inclusive) at screening * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values: * Alanine aminotransferase (ALT) greater than (\>) Upper limit of normal (ULN) +10 percent (%) * Aspartate aminotransferase (AST) \> ULN +20% * Bilirubin \> ULN +20% * Creatinine \> ULN +10% * Absolute neutrophil count \> ULN * Absolute neutrophil count less than (\<) Lower limit of normal (LLN) * Platelet count \> ULN * Platelet count \< LLN * Supine blood pressure at screening outside the range of 90-139 millimeters of mercury (mmHg) for systolic or 50-89 mmHg for diastolic * Heart rate outside the range of 50-90 beats/min at screening * Use of prescription (except contraceptives) or non-prescription medicinal products within 14 days before screening. Occasional use of over-the-counter acetaminophen or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) at their labelled doses is permitted.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
ICON-Salt Lake City Salt Lake City Utah

More Novo Nordisk A/S trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07829406 on ClinicalTrials.gov ↗ ← All trials in the USA